Actelion: latest news - GoINPHARMA
Wednesday, 19 September 2018 - 12:12

Actelion

Biotech sector ensures highest premium among M&A transactions

Analysts from investment bank Bryan, Garnier & Co have issued a report analyzing as many as 1,040 M&A transactions announced over the first 9 months of the year and performed in the Healthcare/Pharma sector. 132 out of the 1,040 acquired…

Actelion Jobs guaranteed

Johnson & Johnson’s managers confirmed the company won’t cut any job in newly-acquired Actelion following the $30bn takeover carried out by the US-based giant. Specifically, JnJ is planning to strengthen its presence in Switzerland, Actelion’s new GM, Jane Griffiths, stated…

Idorsia born from Actelion: a dramatic +37% on first trading day

New pharmaceutical group Idorsia was created yesterday from the acquisition of Actelion by US-based Johnson & Johnson. The new spin-off debuted yesterday in Zurich at the initial price of CHF10, and closed its first day at CHF13.65, totaling a market…

The future of Actelion following acquisition by Johnson & Johnson

Jane Griffiths, the future head of the Actelion unit, acquired by Johnson & Johnson some months ago for $30bn, said in an interview to the WSJ that Actelion will focus on developing and commercializing therapies for pulmonary arterial hypertension (PAH)….

The extraordinary adventure of the Clozels (Actelion)

When, in summer 1997, Jean-Paul Clozel (61, cardiologist) and Martine Clozel (61, pediatrician) founded Actelion in their own garage, funding it with their own savings and even mortgaging their house, they probably did not expect they would sell their firm…

The incredible adventure of the Clozels and their Actelion

Jean-Paul and Martine Clozel founded the Swiss biotech group Actelion. Started in a garage, the group has grown so much over the years to be sold to Johnson & Johnson for $30bn. The Clozels are now embarking on a new…

An analysis of Johnson & Johnson-Actelion deal

The German economic and financial daily Handelsblatt published a long analysis of the agreement regulating the $30bn acquisition of Actelion by US-based Johnson & Johnson. According to the Frankfurt’s daily, the agreement is likely to provide a new standard for…

Deal signed: Johnson & Johnson to acquire Actelion for $30bn

It was announced this morning that Johnson & Johnson has acquired the Swiss group Actelion for $30bn in cash. The deal was pre-announced several days ago. The agreement includes the creation of an independent spin-off, which will have the rich…

J&J, Actelion to reach agreement on price

Johnson & Johnson is reportedly close to reach an agreement with Actelion on a price to acquire the Swiss biotechnology company. Actelion currently has a market value of $25bn and the US giant has reportedly valued it at approximately $28bn….

Johnson & Johnson soon to acquire Actelion

Johnson & Johnson and Actelion are negotiating an agreement under which the Swiss biotech would be acquired for $260 per share (13% premium) and its research center would remain independent. Actelion’s current shareholders could benefit from the deal. Specifically, this…

Actelion sidelines Sanofi and resumes talks with J&J

Unexpected developments in the Actelion saga: the Switzerland-based group announced yesterday it has started exclusive talks with US-based Johnson & Johnson; this implies that talks with Sanofi have been interrupted. The announcement surprised the financial community, which was taking almost…

Sanofi-Actelion deal likely to be announced as soon as next week

Bloomberg reported today that Sanofi is about to successfully conclude talks to acquire Switzerland-based Actelion Ltd., and the deal is likely to be announced as soon as next week. Sanofi reportedly valued Actelion at $275 per share, which would mean…

J&J abandons pursuit of Actelion, Sanofi targets it

Johnson & Johnson seems to have abandoned its plan to acquire Actelion Pharmaceuticals Ltd. and the Switzerland-based group announced on a press release it started talks with another group. Such group is France-based Sanofi, targeting Actelion after failing to acquire…

Is also Sanofi targeting Actelion?

Bloomberg reports that Sanofi is exploring a bid for Switzerland-based Actelion Ltd., targeted by Johnson & Johnson in the last few days, people familiar with the matter said. The French giant has not made a final decision on whether to…

Novartis doesn’t target Actelion

Swiss daily Neue Zürcher Zeitung reported today a statement by Joe Jimenez, Novartis’ CEO, informing that his company will not place any bid for Actelion, already targeted by many multinationals. Jimenez reiterated that Novartis is focusing on bolt-on acquisitions worth…

The market doesn’t like the complicated Actelion-J&J deal

The FT reported yesterday that Actelion’s management is likely to be considering a complicated deal with Johnson & Johnson, under which the Switzerland-based biotech would combine with part of Johnson & Johnson. The market immediately had a negative reaction to…

Actelion confirms approach from Johnson & Johnson

Switzerland-based biotech Actelion confirmed on a press release it has been approached by Johnson & Johnson about a potential acquisition. The news about the US giant likely to take over the top European biotech started circulating on Thursday evening. Actelion’s…

Johnson & Johnson targets Actelion ($17bn)

Bloomberg reported that Johnson & Johnson is likely to be in talks to acquire Switzerland-based Actelion. Actelion is probably Europe’s largest biotech firm and analysts value it at at least $17 bn. The Swiss group has Tracleer (pneumology) as its…